• AbCellera Biologics recently announced that it will share interim Phase 1 data for ABCL635, its potential first-in-class non-hormonal antibody targeting the neurokinin 3 receptor for menopausal vasomotor symptoms, during its first-quarter 2026 earnings call on May 11, 2026.
• This update marks the first clinical readout from AbCellera’s GPCR and ion channel platform, highlighting how its transition into a clinical-stage pipeline is beginning to be tested in humans.
• We’ll now examine how the upcoming first-in-human ABCL635 data, as AbCellera’s lead GPCR program, could reshape its investment narrative.

Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

AbCellera Biologics Investment Narrative Recap

To own AbCellera, you need to believe its antibody discovery engine can translate into valuable clinical assets while it absorbs ongoing losses and heavy R&D spend. The upcoming ABCL635 Phase 1 readout is now the key near term catalyst, because it tests human target engagement and safety in a competitive menopause market. The main risk is that early data underwhelm, which could challenge confidence in both ABCL635 and AbCellera’s broader GPCR platform.

The January 2026 update that ABCL635 had moved into a Phase 1/2 trial, with the first Phase 2 patients already dosed, is especially relevant here. It set expectations for top line Phase 2 results in Q3 2026, framing a clear clinical timeline. The new commitment to share interim Phase 1 data on May 11, 2026, adds an earlier checkpoint on that same path and may influence how investors weigh the Q3 2026 catalyst against execution and cash burn risks.

Yet, while the GPCR data could be encouraging, investors should also be aware that...

AbCellera Biologics' narrative projects $123.3 million revenue and $17.5 million earnings by 2028. This requires 55.4% yearly revenue growth and a $183.2 million earnings increase from -$165.7 million today.

Uncover how AbCellera Biologics' forecasts yield a $9.83 fair value, a 151% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already modeling revenue to reach about US$250.3 million by 2028 and a return to positive earnings, so if ABCL635’s early data shift confidence on clinical risk or timing, those bullish assumptions and more cautious views could both move, reminding you that reasonable investors can look at the same story and reach very different conclusions.

Explore 9 other fair value estimates on AbCellera Biologics - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbCellera Biologics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free AbCellera Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbCellera Biologics' overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 63 companies with promising cash flow potential yet trading below their fair value.
• Explore 25 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.